A
Amr Wahba
2
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Sep 24, 2026
EP 56: GLP-1s and Neuroendocrine Cancer: What Do We Know?
16:51
17:07
17:14
17:23
17:41
29:32

Amr WahbaGUEST
So, for example, some areas in the small bowel, like the ileum, which is sort of the distal or the further part of the small bowels, didn't seem to express as much docking sites for these medications to act upon.

Amr WahbaGUEST
as compared to people with neuroendocrine tumors or cancers in the pancreas or the duodenum.

Amr WahbaGUEST
And so the patients with such tumors would be at a higher risk and so would require closer monitoring.

Amr WahbaGUEST
I think someone with a very low burden of tumors is generally less risk than someone who's got spread tumors throughout their body or a type that is progressively going at a faster rate than we would hope for.

Amr WahbaGUEST
So these are things that I would think of when making a decision or recommendation as to continuing such medications.
12 MINS LATER

Jessica ThomasHOST
So for someone living with neuroendocrine cancer, another important part of this conversation is simply making sure everyone involved in your care plan knows you're taking one.
EP 56: GLP-1s and Neuroendocrine Cancer: What Do We Know?
16:51
17:07
17:14
17:23
17:41
29:32

Amr WahbaGUEST
So, for example, some areas in the small bowel, like the ileum, which is sort of the distal or the further part of the small bowels, didn't seem to express as much docking sites for these medications to act upon.

Amr WahbaGUEST
as compared to people with neuroendocrine tumors or cancers in the pancreas or the duodenum.

Amr WahbaGUEST
And so the patients with such tumors would be at a higher risk and so would require closer monitoring.

Amr WahbaGUEST
I think someone with a very low burden of tumors is generally less risk than someone who's got spread tumors throughout their body or a type that is progressively going at a faster rate than we would hope for.

Amr WahbaGUEST
So these are things that I would think of when making a decision or recommendation as to continuing such medications.
12 MINS LATER

Jessica ThomasHOST
So for someone living with neuroendocrine cancer, another important part of this conversation is simply making sure everyone involved in your care plan knows you're taking one.